SELLAS Life Sciences (SLS) Income towards Parent Company (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Income towards Parent Company of -$15.1 million for Q1 2026, down 140.35% year-over-year from $37.3 million in Q1 2025, and down 80.17% quarter-over-quarter from -$8.4 million in Q4 2025.
SELLAS Life Sciences (SLS) Income towards Parent Company (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Income towards Parent Company for 15 consecutive years, with -$15.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 140.35% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$39.6 million (down 39.35% YoY), while the FY2025 annual figure was -$51.1 million, up 2.42% from the prior year.
- Income towards Parent Company fell to -$15.1 million in Q1 2026 per SLS's latest filing, from -$8.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$6.3 million in Q1 2025 and bottomed at -$16.8 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$9.3 million across 5 years, with a median of -$8.7 million in 2022.
- Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 617.91% — and 2025, when it soared 35.73%.
- SELLAS Life Sciences' Income towards Parent Company stood at -$9.6 million in 2022, then advanced by 14.19% to -$8.3 million in 2023, then increased by 15.21% to -$7.0 million in 2024, then declined by 19.05% to -$8.4 million in 2025, then tumbled by 80.17% to -$15.1 million in 2026.
- Business Quant data shows SLS's Income towards Parent Company at -$15.1 million in Q1 2026, -$8.4 million in Q4 2025, and -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.97 Mn |
| Mar 31, 2026 | -15.05 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -8.93 Mn |
| Mar 31, 2025 | -6.26 Mn |
| Dec 31, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.43 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Sep 30, 2023 | -9.46 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -11.38 Mn |
| Dec 31, 2022 | -9.65 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -16.84 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | -7.08 Mn |